Tradestie Institutional Equity Comparison Engine
BCRX vs CVM โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
BCRX Overall Edge
BCRX Captures Institutional Edge (4โ0 Pillars ยท 7โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to BioCryst Pharmaceuticals Inc (BCRX) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, BCRX trades at 8.9x Forward P/E with 48.8% operating margin (+13.1% YoY revenue) versus CVM at 23.0x Forward P/E and 0.0% operating margin (-62.7% YoY). In options structure, BCRX sits in BREAKDOWN (12th %ile IV; Dealer Gamma Walls on Pro) against CVM sits in BREAKDOWN (N/A IV; Dealer Gamma Walls on Pro).
Valuation Winner
BCRX
BCRX 8.9x vs CVM 23.0x Fwd P/E
Growth & Margin Winner
BCRX
Op Margin 48.8% vs 0.0% ยท YoY +13.1% vs -62.7%
Momentum & Technical Winner
BCRX
1Y +9.1% vs -77.5% ยท 52W Pos 26% vs 10%
Options & Structure Winner
BCRX
BREAKDOWN (12th %ile IV) vs BREAKDOWN (N/A IV)
BCRX
NASDAQ
BioCryst Pharmaceuticals Inc
Biological Products, (No Disgnostic Substances)
$7.53
-1.05% 1D
Market Cap
$1.9B
1M Return
-3.34%
1Y Return
+9.13%
Forward P/E
8.9x
Unified AI Score
43.3 / 100
HOLD
Tech 24.0
Fund 59.0
Flow 67.0
Mom 68.9
CVM
NYSE American
Cel-Sci Corporation
Biological Products, (No Disgnostic Substances)
$1.59
+24.22% 1D
Market Cap
$20.9M
1M Return
-11.17%
1Y Return
-77.48%
Forward P/E
23.0x
Unified AI Score
56.6 / 100
HOLD
Tech 60.0
Fund 54.0
Flow 50.0
Mom 60.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
BCRX +9.13%
CVM -77.48%
Spread: +82.34 pp (BCRX Lead)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | BCRX Revenue | CVM Revenue | BCRX Op. Margin | CVM Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | $20M | N/A | -456.2% | N/A | BCRX |
| FY2019 | $50M | N/A | -203.7% | N/A | BCRX |
| FY2020 | $20M | N/A | -981.1% | N/A | BCRX |
| FY2021 | $160M | N/A | -113.1% | N/A | BCRX |
| FY2022 | $270M | N/A | -54.8% | N/A | BCRX |
| FY2023 | $330M | N/A | -31.3% | N/A | BCRX |
| FY2024 | $450M | N/A | -0.6% | N/A | BCRX |
| FY2025 | $870M | N/A | 39.0% | N/A | BCRX |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | BCRX | CVM | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $1.9B | $20.9M | Larger Scale | BCRX |
| Trailing P/E Ratio Valuation | 13.0x | 23.0x | Lower Multiple | BCRX |
| Forward P/E Ratio Valuation | 8.9x | 23.0x | Lower Multiple | BCRX |
| Revenue Growth (YoY) Growth | +13.1% | -62.7% | Higher Growth | BCRX |
| Operating Margin (TTM) Profitability | 48.8% | 0.0% | Higher Margin | BCRX |
| Net Profit Margin Profitability | -37.4% | 0.0% | Higher Margin | CVM |
| Return on Equity (ROE) Capital Efficiency | -1925.4% | -252.5% | Higher ROE | CVM |
| 52-Week Range Position Momentum | 26% ($6โ$11) | 10% ($1โ$8) | Stronger Trend | BCRX |
| Beta / 30D Volatility Risk Regime | 0.77ฮฒ ยท 42% Vol | 0.65ฮฒ ยท 120% Vol | Lower Realized Risk | BCRX |
| Unified Institutional Score Composite Signal | 43.3 / 100 (HOLD) | 56.6 / 100 (HOLD) | Higher Composite | CVM |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full BCRX vs CVM Buy Guide
BCRX
BREAKDOWN
92d in phase ยท OBV DISTRIBUTION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
12th %ile
IV Regime
Compressed (<25th %ile)
CVM
BREAKDOWN
29d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither BCRX nor CVM registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.